ZNRF3 and adrenal cortex carcinoma: Regarding the outcome analysis, 64.1% of patients with ACC who progressed to death presented with a low level of ZNRF3 protein expression and had a median survival of 19 months (X2(1) = 4.716; p = 0.030; Chi-squared test).